title: Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis.
abstract: Advanced glycation end products (AGEs) accumulate in serum and tissues of patients with chronic renal failure, even in the absence of diabetes, and a different clearance of these species has been observed by hemodialysis and peritoneal dialysis (CAPD). Furthermore, it has been shown that not only AGE but also 1,2-dicarbonyl compounds are formed during heat sterilization of glucose-based peritoneal dialysis fluids. Therefore, we investigated the level of some AGEs (pentosidine and free pentosidine) and dicarbonyl compounds (glyoxal and methylglyoxal) in end-stage renal disease patients subjected to peritoneal dialysis. Samples (20 from healthy subjects, 16 from uremic patients before and after 12 h of peritoneal dialysis) were analyzed, and the plasma and dialysate levels of glyoxal, methylglyoxal, pentosidine, and free pentosidine were determined. In plasma of uremic patients, mean values of pentosidine showed a small decrease after dialysis and were always higher than those of healthy control subjects. An analogous trend was observed for free pentosidine. In the case of peritoneal dialysate, no pentosidine and free pentosidine were found at time zero, whereas both compounds were detected after 12 h of dialysis. Glyoxal and methylglyoxal mean levels showed a decrease in plasma after dialysis even if their values were always higher than those of healthy control subjects. Surprisingly, an analogous trend was observed also in dialysate. These results might indicate that glyoxal and methylglyoxal already present in the dialysis fluid react with the peritoneal matrix proteins, accounting for the gradual loss of peritoneal membrane function that is often observed in patients subjected to CAPD for a long time.
authors.affiliation: Dipartimento di Scienze Mediche e Chirurgiche, Cattedra di Malattie del Metabolismo, Via Giustiniani 2, 35100 Padova, Italy. annunziata.lapolla@unipd.it
authors.forename: A
authors.initials: A
authors.lastname: Lapolla
authors.forename: R
authors.initials: R
authors.lastname: Flamini
authors.forename: A
authors.initials: A
authors.lastname: Lupo
authors.forename: N C
authors.initials: NC
authors.lastname: Aricò
authors.forename: C
authors.initials: C
authors.lastname: Rugiu
authors.forename: R
authors.initials: R
authors.lastname: Reitano
authors.forename: M
authors.initials: M
authors.lastname: Tubaro
authors.forename: E
authors.initials: E
authors.lastname: Ragazzi
authors.forename: R
authors.initials: R
authors.lastname: Seraglia
authors.forename: P
authors.initials: P
authors.lastname: Traldi
mesh_terms: D000368:Aged; D001798:Blood Proteins / Q000032:analysis; D005260:Female; D006037:Glyoxal / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011765:Pyruvaldehyde / Q000097:blood*; D014511:Uremia / Q000097:blood* / Q000628:therapy
chemical_list: D001798:Blood Proteins; D006037:Glyoxal; D011765:Pyruvaldehyde